https://stock.noler.com/us/stock/celyad-oncology-sa https://stock.noler.com/us/stock/celyad-oncology-sa/accruals-and-deferred-income-classified-as-current https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-assumption-of-discount-rates https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-assumption-of-expected-rates-of-inflation https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-assumption-of-expected-rates-of-salary-increases https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-assumption-of-retirement-age https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-gains-losses-arising-from-changes-in-demographic-assumptions-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-gains-losses-arising-from-changes-in-financial-assumptions-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/actuarial-gains-losses-arising-from-experience-adjustments-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/additions-other-than-through-business-combinations-property-plant-and-equipment https://stock.noler.com/us/stock/celyad-oncology-sa/additions-to-rightofuse-assets https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-amortisation-expense https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-decrease-increase-in-other-current-assets https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-decrease-increase-in-prepaid-expenses https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-decrease-increase-in-trade-account-receivable https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-decrease-increase-in-trade-and-other-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-depreciation-expense https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-gain-loss-on-disposals-property-plant-and-equipment https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-gains-losses-on-change-in-fair-value-of-derivatives https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-increase-decrease-in-deferred-income-including-contract-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-increase-decrease-in-employee-benefit-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-increase-decrease-in-other-current-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-increase-decrease-in-trade-account-payable https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-increase-decrease-in-trade-and-other-payables https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-share-based-payments https://stock.noler.com/us/stock/celyad-oncology-sa/adjustments-for-unrealised-foreign-exchange-losses-gains https://stock.noler.com/us/stock/celyad-oncology-sa/advances https://stock.noler.com/us/stock/celyad-oncology-sa/applicable-tax-rate https://stock.noler.com/us/stock/celyad-oncology-sa/average-effective-tax-rate https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-exercised-or-vested-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-exercised-or-vested-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-expired-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-expired-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-forfeited-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-forfeited-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-granted-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-granted-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-outstanding-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/average-exercise-price-of-other-equity-instruments-outstanding-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/celyad-oncology-sa/basic-and-diluted-earnings-loss-per-share https://stock.noler.com/us/stock/celyad-oncology-sa/basic-earnings-loss-per-share https://stock.noler.com/us/stock/celyad-oncology-sa/borrowings https://stock.noler.com/us/stock/celyad-oncology-sa/capital-redemption-reserve https://stock.noler.com/us/stock/celyad-oncology-sa/cash https://stock.noler.com/us/stock/celyad-oncology-sa/cash-and-cash-equivalents https://stock.noler.com/us/stock/celyad-oncology-sa/cash-flows-from-used-in-decrease-increase-in-shortterm-deposits-and-investments https://stock.noler.com/us/stock/celyad-oncology-sa/cash-flows-from-used-in-financing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/cash-flows-from-used-in-investing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/cash-flows-from-used-in-operating-activities https://stock.noler.com/us/stock/celyad-oncology-sa/cash-flows-used-in-obtaining-control-of-subsidiaries-or-other-businesses-classified-as-investing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/cash-outflow-for-leases https://stock.noler.com/us/stock/celyad-oncology-sa/comprehensive-income https://stock.noler.com/us/stock/celyad-oncology-sa/comprehensive-income-attributable-to-owners-of-parent https://stock.noler.com/us/stock/celyad-oncology-sa/contributions-to-plan-by-employer-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/contributions-to-plan-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/cost-of-sales https://stock.noler.com/us/stock/celyad-oncology-sa/cover-page-shares-outstanding https://stock.noler.com/us/stock/celyad-oncology-sa/current-advances https://stock.noler.com/us/stock/celyad-oncology-sa/current-assets https://stock.noler.com/us/stock/celyad-oncology-sa/current-finance-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/current-financial-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/current-investments https://stock.noler.com/us/stock/celyad-oncology-sa/current-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/current-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/current-payables-on-social-security-and-taxes-other-than-income-tax https://stock.noler.com/us/stock/celyad-oncology-sa/current-prepaid-expenses https://stock.noler.com/us/stock/celyad-oncology-sa/current-service-cost-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/current-tax-expense-income https://stock.noler.com/us/stock/celyad-oncology-sa/current-trade-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/current-value-added-tax-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/deferred-tax-assets https://stock.noler.com/us/stock/celyad-oncology-sa/deferred-tax-expense-income https://stock.noler.com/us/stock/celyad-oncology-sa/deferred-tax-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/defined-benefit-obligation-at-present-value https://stock.noler.com/us/stock/celyad-oncology-sa/deposits-from-banks https://stock.noler.com/us/stock/celyad-oncology-sa/depreciation-expense https://stock.noler.com/us/stock/celyad-oncology-sa/depreciation-rightofuse-assets https://stock.noler.com/us/stock/celyad-oncology-sa/description-of-growth-rate-used-to-extrapolate-cash-flow-projections https://stock.noler.com/us/stock/celyad-oncology-sa/discount-rate-used-in-current-measurement-of-fair-value-less-costs-of-disposal https://stock.noler.com/us/stock/celyad-oncology-sa/disposals-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/celyad-oncology-sa/effect-of-exchange-rate-changes-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/celyad-oncology-sa/employee-benefits-expense https://stock.noler.com/us/stock/celyad-oncology-sa/employee-contributions https://stock.noler.com/us/stock/celyad-oncology-sa/equity https://stock.noler.com/us/stock/celyad-oncology-sa/equity-and-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/expense-from-share-based-payment-transactions-with-employees https://stock.noler.com/us/stock/celyad-oncology-sa/expense-relating-to-shortterm-leases-for-which-recognition-exemption-has-been-used https://stock.noler.com/us/stock/celyad-oncology-sa/expense-relating-to-variable-lease-payments-not-included-in-measurement-of-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/finance-costs https://stock.noler.com/us/stock/celyad-oncology-sa/finance-income https://stock.noler.com/us/stock/celyad-oncology-sa/finance-income-cost https://stock.noler.com/us/stock/celyad-oncology-sa/finance-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/financial-assets https://stock.noler.com/us/stock/celyad-oncology-sa/financial-assets-at-fair-value https://stock.noler.com/us/stock/celyad-oncology-sa/financial-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/financial-liabilities-at-fair-value https://stock.noler.com/us/stock/celyad-oncology-sa/gain-loss-on-remeasurement-of-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/gains-losses-on-exchange-differences-on-translation-net-of-tax https://stock.noler.com/us/stock/celyad-oncology-sa/gains-on-disposals-of-property-plant-and-equipment https://stock.noler.com/us/stock/celyad-oncology-sa/general-and-administrative-expense https://stock.noler.com/us/stock/celyad-oncology-sa/gross-finance-lease-obligations https://stock.noler.com/us/stock/celyad-oncology-sa/gross-profit https://stock.noler.com/us/stock/celyad-oncology-sa/impairment-loss https://stock.noler.com/us/stock/celyad-oncology-sa/impairment-loss-recognised-in-profit-or-loss-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/celyad-oncology-sa/impairment-loss-recognised-in-profit-or-loss-trade-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/income-from-subleasing-rightofuse-assets https://stock.noler.com/us/stock/celyad-oncology-sa/income-tax-expense https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-in-cash-and-cash-equivalents https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-in-cash-and-cash-equivalents-before-effect-of-exchange-rate-changes https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-in-contingent-liabilities-recognised-in-business-combination https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-in-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-acquisition-of-subsidiary https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-appropriation-of-retained-earnings https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-exercise-of-warrants-equity https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-net-exchange-differences-deferred-tax-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-share-based-payment-transactions https://stock.noler.com/us/stock/celyad-oncology-sa/increase-decrease-through-transactions-with-owners https://stock.noler.com/us/stock/celyad-oncology-sa/insurance-expense https://stock.noler.com/us/stock/celyad-oncology-sa/intangible-assets-and-goodwill https://stock.noler.com/us/stock/celyad-oncology-sa/interest-expense-income-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/interest-expense-on-bank-loans-and-overdrafts https://stock.noler.com/us/stock/celyad-oncology-sa/interest-expense-on-finance-leases https://stock.noler.com/us/stock/celyad-oncology-sa/interest-expense-on-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/interest-income-on-deposits https://stock.noler.com/us/stock/celyad-oncology-sa/investment-accounted-for-using-equity-method https://stock.noler.com/us/stock/celyad-oncology-sa/issue-of-equity https://stock.noler.com/us/stock/celyad-oncology-sa/issued-capital https://stock.noler.com/us/stock/celyad-oncology-sa/lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/liability-asset-of-defined-benefit-plans https://stock.noler.com/us/stock/celyad-oncology-sa/longterm-borrowings https://stock.noler.com/us/stock/celyad-oncology-sa/longterm-onerous-contracts-provision https://stock.noler.com/us/stock/celyad-oncology-sa/losses-on-disposals-of-property-plant-and-equipment https://stock.noler.com/us/stock/celyad-oncology-sa/net-deferred-tax-assets https://stock.noler.com/us/stock/celyad-oncology-sa/net-deferred-tax-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/net-investment-in-finance-lease https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-advances https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-assets https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-assets-or-disposal-groups-classified-as-held-for-sale https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-finance-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-financial-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-lease-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-provisions https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-provisions-for-employee-benefits https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/noncurrent-trade-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-employees https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-instruments-other-equity-instruments-granted https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-other-equity-instruments-exercised-or-vested-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-other-equity-instruments-expired-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-other-equity-instruments-forfeited-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-other-equity-instruments-outstanding-in-share-based-payment-arrangement https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-shares-issued https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-shares-issued-and-fully-paid https://stock.noler.com/us/stock/celyad-oncology-sa/number-of-shares-outstanding https://stock.noler.com/us/stock/celyad-oncology-sa/oci-net-of-tax-gains-losses-on-remeasurements-of-defined-benefit-plans https://stock.noler.com/us/stock/celyad-oncology-sa/oci-that-will-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/celyad-oncology-sa/oci-that-will-not-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/celyad-oncology-sa/onerous-contracts-provision https://stock.noler.com/us/stock/celyad-oncology-sa/operating-expense https://stock.noler.com/us/stock/celyad-oncology-sa/other-comprehensive-income https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-assets https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-financial-assets https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-financial-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-payables https://stock.noler.com/us/stock/celyad-oncology-sa/other-current-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/other-employee-expense https://stock.noler.com/us/stock/celyad-oncology-sa/other-expense-by-nature https://stock.noler.com/us/stock/celyad-oncology-sa/other-income https://stock.noler.com/us/stock/celyad-oncology-sa/other-noncurrent-assets https://stock.noler.com/us/stock/celyad-oncology-sa/other-noncurrent-financial-assets https://stock.noler.com/us/stock/celyad-oncology-sa/other-noncurrent-liabilities https://stock.noler.com/us/stock/celyad-oncology-sa/other-noncurrent-payables https://stock.noler.com/us/stock/celyad-oncology-sa/other-operating-income-expense https://stock.noler.com/us/stock/celyad-oncology-sa/other-reserves https://stock.noler.com/us/stock/celyad-oncology-sa/other-revenue https://stock.noler.com/us/stock/celyad-oncology-sa/other-tax-effects-for-reconciliation-between-accounting-profit-and-tax-expense-income https://stock.noler.com/us/stock/celyad-oncology-sa/par-value-per-share https://stock.noler.com/us/stock/celyad-oncology-sa/payments-in-respect-of-settlements-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/payments-of-finance-lease-liabilities-classified-as-financing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/plan-assets-at-fair-value https://stock.noler.com/us/stock/celyad-oncology-sa/postemployment-benefit-expense-defined-benefit-plans https://stock.noler.com/us/stock/celyad-oncology-sa/postemployment-benefit-expense-defined-contribution-plans https://stock.noler.com/us/stock/celyad-oncology-sa/proceeds-from-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/proceeds-from-disposals-of-property-plant-and-equipment-intangible-assets-other-than-goodwill-investment-property-and-other-noncurrent-assets https://stock.noler.com/us/stock/celyad-oncology-sa/proceeds-from-government-grants-classified-as-financing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/proceeds-from-issuing-shares https://stock.noler.com/us/stock/celyad-oncology-sa/proceeds-from-sales-of-investments-other-than-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/celyad-oncology-sa/profit-loss https://stock.noler.com/us/stock/celyad-oncology-sa/profit-loss-before-tax https://stock.noler.com/us/stock/celyad-oncology-sa/profit-loss-from https://stock.noler.com/us/stock/celyad-oncology-sa/profit-loss-from-operating-activities https://stock.noler.com/us/stock/celyad-oncology-sa/property-plant-and-equipment https://stock.noler.com/us/stock/celyad-oncology-sa/purchase-of-intangible-assets-classified-as-investing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/purchase-of-investments-other-than-investments-accounted-for-using-equity-method https://stock.noler.com/us/stock/celyad-oncology-sa/purchase-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/raw-materials-and-consumables-used https://stock.noler.com/us/stock/celyad-oncology-sa/receivables-from-taxes-other-than-income-tax https://stock.noler.com/us/stock/celyad-oncology-sa/rental-expense https://stock.noler.com/us/stock/celyad-oncology-sa/repayments-of-borrowings-classified-as-financing-activities https://stock.noler.com/us/stock/celyad-oncology-sa/research-and-development https://stock.noler.com/us/stock/celyad-oncology-sa/retained-earnings https://stock.noler.com/us/stock/celyad-oncology-sa/return-on-plan-assets-net-defined-benefit-liability-asset https://stock.noler.com/us/stock/celyad-oncology-sa/revenue https://stock.noler.com/us/stock/celyad-oncology-sa/revenue-from-sale-of-goods https://stock.noler.com/us/stock/celyad-oncology-sa/reversed-unsettled-liabilities-contingent-liabilities-recognised-in-business-combination https://stock.noler.com/us/stock/celyad-oncology-sa/rightofuse-assets https://stock.noler.com/us/stock/celyad-oncology-sa/sga-expense https://stock.noler.com/us/stock/celyad-oncology-sa/share-of-profit-loss-of-associates-and-joint-ventures-accounted-for-using-equity-method https://stock.noler.com/us/stock/celyad-oncology-sa/share-of-profit-loss-of-joint-ventures-accounted-for-using-equity-method https://stock.noler.com/us/stock/celyad-oncology-sa/share-premium https://stock.noler.com/us/stock/celyad-oncology-sa/shortterm-borrowings https://stock.noler.com/us/stock/celyad-oncology-sa/shortterm-deposits-classified-as-cash-equivalents https://stock.noler.com/us/stock/celyad-oncology-sa/shortterm-employee-benefits-accruals https://stock.noler.com/us/stock/celyad-oncology-sa/shortterm-investments-classified-as-cash-equivalents https://stock.noler.com/us/stock/celyad-oncology-sa/shortterm-onerous-contracts-provision https://stock.noler.com/us/stock/celyad-oncology-sa/social-security-contributions https://stock.noler.com/us/stock/celyad-oncology-sa/surplus-deficit-in-plan https://stock.noler.com/us/stock/celyad-oncology-sa/tax-effect-of-expense-not-deductible-in-determining-taxable-profit-tax-loss https://stock.noler.com/us/stock/celyad-oncology-sa/tax-expense-income-at-applicable-tax-rate https://stock.noler.com/us/stock/celyad-oncology-sa/total-assets https://stock.noler.com/us/stock/celyad-oncology-sa/trade-and-other-current-payables-to-trade-suppliers https://stock.noler.com/us/stock/celyad-oncology-sa/trade-and-other-current-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/trade-and-other-payables https://stock.noler.com/us/stock/celyad-oncology-sa/trade-and-other-receivables https://stock.noler.com/us/stock/celyad-oncology-sa/treasury-shares https://stock.noler.com/us/stock/celyad-oncology-sa/unused-tax-losses-for-which-no-deferred-tax-asset-recognised https://stock.noler.com/us/stock/celyad-oncology-sa/wages-and-salaries https://stock.noler.com/us/stock/celyad-oncology-sa/weighted-average-shares